Yantai Zhenghai Bio-Tech300653.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Yantai Zhenghai Bio-Tech (300653.SZ) trades at a P/E of 38.50x, P/B of 3.07x, P/S of 8.39x, and a dividend yield of 1.86%.
Longitudinal percentile comparison: P/E sits at the 29th percentile over the trailing 10Y window (vs. 63rd percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 10th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 52nd percentile within its industry and the 51st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.86%, ranking at the 74th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 24.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Yantai Zhenghai Bio-Tech operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300653 · SZSE: 300653 · 300653
Want the full picture on whether Yantai Zhenghai Bio-Tech (300653.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 38.50 | ||||||
| P/B (MRQ) | 3.07 | ||||||
| P/S (TTM) | 8.39 | ||||||
| Dividend Yield | 1.86% | ||||||
| Buyback + Div Yield | 1.86% |